Drug Study Final 1
Drug Study Final 1
Drug Study Final 1
Route:
Oral or
intramuscu
lar
administrat
ion.
Date Drug name Drawing Classifi Dosage/ Indicati Mechanism Side nursing
cation on of action effect responsibilities
Time/route
Route:
Generi Biperiden Dosage: Biperide Biperiden hallucinat Communicate with the patient in a calm
c is Typically n is exerts its ions and reassuring manner. Use clear and
name : classified starts at 2 indicate therapeutic simple language to convey instructions
as an mg orally, d for the effects by confusion or information. Validate the patient's
Biperid anticholine two to treatme blocking , feelings and experiences while gently
en rgic agent. three nt of the action agitation, guiding them back to reality.
times Parkins of hyperacti
daily, and on's acetylcholi vity engaging in activities that distract from
can be disease ne in the hallucinations or providing relaxation
adjusted and central techniques to reduce agitation.
based on drug- nervous
the induced system. It
patient's extrapyr primarily
Brand response. amidal acts on
name: sympto muscarinic
Route: ms. receptors,
Akinet Oral particularly
on administr M1
ation. receptors,
thereby
reducing
the excess
cholinergic
activity
associated
with
Parkinson'
s disease
and certain
drug-
induced
movement
disorders.
Dat Drug Drawin Classific Dosage/ Indicatio Mechanism Side Effects: Nursing Responsibilities:
e Name g ation: n: of Action:
Time/
Route:
Route
Brand
Name:
K-Lyte
Date Name of Drawing Classific Dosage/ Indicatio Mechanis Side Effects Nursing Responsibilities
Drug ation Time/Rou n m of
te Action
Sleepiness
Disorder .